SMAD3 and diabetes mellitus: A pharmacogenetic analysis using a genome‐wide approach in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial identified HSD17B3, SMAD3, and IPO11 as genetic markers of fenofibrate response.17